ALBUQUERQUE – January 8, 2024 – New Mexico Heart Institute/Lovelace Medical Group (NMHI) has enrolled the first patient in the world in the RECOVER IV randomized study comparing management strategies for patients with cardiogenic shock using the Impella CP®, an FDA-approved temporary heart pump, versus standard of care.